CARLSBAD, Calif., Sept. 14 /PRNewswire-FirstCall/ — Isis
Pharmaceuticals, Inc. (Nasdaq:
ISIS), the leader in antisense therapeutics, today announced
that management will present a company overview at UBS’ Global Life
Sciences Conference on Tuesday, September 21, 2010 at 4:00 p.m. ET
at the Grand Hyatt New York.
A live audio webcast of the presentation will be available on
the “Investors & Media” section of the Company’s Web site, www.isispharm.com. A
replay of the presentation will be available on the Isis Web site
within 48 hours and will be archived for a limited time.
ABOUT ISIS PHARMACEUTICALS, INC.
Isis is exploiting its expertise in RNA to discover and develop
novel drugs for its product pipeline and for its partners.
The Company has successfully commercialized the world’s first
antisense drug and has 23 drugs in development. Isis’ drug
development programs are focused on treating cardiovascular,
metabolic, and severe neurodegenerative diseases and cancer.
Isis’ partners are developing antisense drugs invented by
Isis to treat a wide variety of diseases. Isis and Alnylam
Pharmaceuticals are joint owners of Regulus Therapeutics Inc., a
company focused on the discovery, development and commercialization
of microRNA therapeutics. Isis also has made significant
innovations beyond human therapeutics resulting in products that
other companies, including Abbott, are commercializing. As an
innovator in RNA-based drug discovery and development, Isis is the
owner or exclusive licensee of over 1,600 issued patents worldwide.
Additional information about Isis is available at www.isispharm.com.